One of the immune
system’s oldest branches, called complement, may be influencing the severity of
COVID disease, according to a new study from researchers at Columbia University
Irving Medical Center.
Among other findings linking complement to COVID, the
researchers found that people with age-related macular degeneration — a
disorder caused by overactive complement — are at greater risk of developing
severe complications and dying from COVID.
The connection with complement suggests that existing
drugs that inhibit the complement system could help treat patients with severe
disease.
The study was published on
Aug. 3 in Nature Medicine.
The authors also found evidence that clotting activity
is linked to COVID severity and that mutations in certain complement and
coagulation genes are associated with hospitalization of COVID patients.
“Together these results provide important insights
into the pathophysiology of COVID-19 and paint a picture for the role of
complement and coagulation pathways in determining clinical outcomes of
patients infected with SARS-CoV-2,” says Sagi Shapira, PhD, MPH, who led the
study with Nicholas Tatonetti, PhD, both professors at Columbia University
Vagelos College of Physicians and Surgeons.
Findings
Stem from Study of Coronavirus Mimicry
The idea to investigate the role of coagulation and
complement in COVID began with a sweeping survey of viral mimicry across all
viruses on earth — over 7,000 in all.
“Viruses have proteins that can mimic certain host
proteins to trick the host’s cells into aiding the virus with completing its
life cycle,” Shapira says. “Beyond the fundamental biological questions that we
were interested in addressing, based on our previous work and the work of
others, we suspected that identifying those mimics could provide clues about
how viruses cause disease.”
Coronaviruses, the survey found, are masters of
mimicry, particularly with proteins involved in coagulation and proteins that
make up complement, one of the oldest branches of the human immune system.
Complement proteins work a bit like antibodies and
help eliminate pathogens by sticking to viruses and bacteria and marking them
for destruction. Complement can also increase coagulation and inflammation in
the body. “Unchecked, these systems can also be quite detrimental,” says
Shapira.
“The new coronavirus — by mimicking complement or
coagulation proteins — might drive both systems into a hyperactive state.”
Macular
Degeneration Associated with Greater COVID Mortality
If complement and coagulation influence severity of
COVID, people with pre-existing hyperactive complement or coagulation disorders
should be more susceptible to the virus.
That led Shapira and Tatonetti to look at COVID
patients with macular degeneration, an eye disease caused by overactive
complement, as well as common coagulation disorders like thrombosis and
hemorrhage.
Among 11,000 COVID patients who came to Columbia
University Irving Medical Center with suspected COVID-19, the researchers found
that over 25% of those with age-related macular degeneration died, compared to
the average mortality rate of 8.5%, and roughly 20% required intubation. The
greater mortality and intubation rates could not be explained by differences in
the age or sex of the patients.
“Complement is also more active in obesity and
diabetes,” Shapira says, “and may help explain, at least in part, why people
with those conditions also have a greater mortality risk from COVID.”
People with a history of coagulation disorders also
were at increased risk of dying from COVID infection.
Coagulation
and Complement Pathways Activated
The researchers then examined how gene activity
differed in people infected with the coronavirus.
That analysis revealed a signature in COVID-infected
patients indicating that the virus engages and induces robust activation of the
body’s complement and coagulation systems.
“We found that complement is one of the most
differentially expressed pathways in SARS-CoV-2 infected patients,” Tatonetti
says. “As part of the immune system, you would expect to see complement
activated, but it seems over and above what you’d see in other infections like
the flu.”
Some
Coagulation and Complement Genes are Associated with Hospitalization
More evidence linking severe COVID with coagulation
and complement comes from a genetic analysis of thousands of COVID patients
from the U.K. Biobank, which contains medical records and genetic data on half
a million people.
The authors found that variants of several genes that
influence complement or coagulation activity are associated with more severe
COVID symptoms that required hospitalization.
“These variants are not necessarily going to determine
someone’s outcome,” Shapira says. “But this finding is another line of evidence
that complement and coagulation pathways participate in the morbidity and
mortality associated with COVID-19.”
Targeting
Coagulation and Complement
Physicians treating COVID patients have noticed
coagulation issues since the beginning of the pandemic, and several clinical
trials are underway to determine the best way to use existing anti-coagulation
treatments.
Complement inhibitors are currently used in relatively
rare diseases, but at least one clinical trial is testing the idea with COVID
patients.
“I think our findings provide a stronger foundation
for the idea that coagulation and complement play a role in COVID,” Tatonetti
says, “and will hopefully inspire others to evaluate this hypothesis and see if
it’s something that can be useful for fighting the ongoing pandemic.”
Source: https://www.cuimc.columbia.edu/news/ancient-part-immune-system-may-underpin-severe-covid
Journal article: https://www.nature.com/articles/s41591-020-1021-2
Source: https://myfusimotors.com/2020/08/05/ancient-part-of-immune-system-may-underpin-severe-covid/
No comments:
Post a Comment